BIAF Stock Price, bioAffinity Technologies, . Quote, Chart

Market Summary

USD2.24-0.21

Market Closed

-8.57%

BIAF Stock Price

View Fullscreen

BIAF RSI Chart

BIAF Valuation

Market Cap

26.1M

Price/Earnings (Trailing)

-3.12

Price/Sales (Trailing)

5.29

EV/EBITDA

-2.99

Price/Free Cashflow

-3.79

BIAF Price/Sales (Trailing)

BIAF Profitability

Operating Margin

99.99%

EBT Margin

-169.16%

Return on Equity

-159.14%

Return on Assets

-103.94%

Free Cashflow Yield

-26.37%

BIAF Fundamentals

BIAF Revenue

Revenue (TTM)

4.9M

Rev. Growth (Yr)

17.7K%

Rev. Growth (Qtr)

8.72%

BIAF Earnings

Earnings (TTM)

-8.4M

Earnings Growth (Yr)

-27.99%

Earnings Growth (Qtr)

17.33%

Breaking Down BIAF Revenue

Last 7 days

12%

Last 30 days

-23.0%

Last 90 days

47.4%

How does BIAF drawdown profile look like?

BIAF Financial Health

Current Ratio

2.22

BIAF Investor Care

Shares Dilution (1Y)

36.84%

Diluted EPS (TTM)

-0.93

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	4.9M	0	0	0
2023	636.7K	1.3M	1.9M	2.5M
2022	0	0	0	4.8K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of bioAffinity Technologies, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 08, 2024	zannes maria	sold (taxes)	-74,899	2.65	-28,264	president & ceo
Apr 08, 2024	zannes maria	acquired	75,223	1.16	64,848	president & ceo
Apr 04, 2024	zannes timothy p	acquired	75,223	1.16	64,848	secretary, evp, gen. counsel
Apr 04, 2024	zannes timothy p	sold (taxes)	-74,900	2.58	-29,031	secretary, evp, gen. counsel
Apr 03, 2024	girgenti steven	acquired	75,223	1.16	64,848	-
Apr 03, 2024	girgenti steven	sold (taxes)	-74,901	2.24	-33,438	-
Feb 26, 2024	anderson robert a.	acquired	74,899	1.155	64,848	-
Feb 16, 2024	girgenti steven	acquired	60,000	1.52	39,474	executive chairman
Jan 31, 2024	zannes maria	acquired	-	-	23,885	president, ceo
Jan 31, 2024	girgenti steven	acquired	-	-	11,943	executive chairman

Which funds bought or sold BIAF recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	9,328	35,552	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-8.00	-	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	unchanged	-	138,653	156,204	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	13.04	2,405	6,761	-%
May 15, 2024	CAPTRUST FINANCIAL ADVISORS	reduced	-30.09	-2,323	56,328	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	sold off	-100	-31,825	-	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-0.82	16,178	18,860	-%
May 14, 2024	NORTHERN TRUST CORP	new	-	27,597	27,597	-%
May 14, 2024	Qube Research & Technologies Ltd	unchanged	-	20.00	77.00	-%
May 14, 2024	Sheaff Brock Investment Advisors, LLC	new	-	20,200	20,200	-%

Are Funds Buying or Selling BIAF?

Are funds buying BIAF calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BIAF

No. of Funds

Recent SEC filings of bioAffinity Technologies, Inc.

View All Filings

Date Filed	Form Type	Document
May 16, 2024	8-K	Current Report
May 15, 2024	10-Q	Quarterly Report
Apr 24, 2024	4	Insider Trading
Apr 24, 2024	4	Insider Trading
Apr 24, 2024	4	Insider Trading
Apr 17, 2024	424B3	Prospectus Filed
Apr 15, 2024	EFFECT	EFFECT
Apr 15, 2024	ARS	ARS
Apr 15, 2024	DEF 14A	DEF 14A
Apr 15, 2024	DEFA14A	DEFA14A

Peers (Alternatives to bioAffinity Technologies, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	196.9B	23.7B	11.04%	17.40%	44.73	8.29	-8.94%	-35.91%
A	45.2B	6.7B	14.64%	19.44%	36.57	6.71	-2.81%	-6.58%
IDXX	44.9B	3.7B	13.71%	10.52%	51.83	12.06	8.57%	23.94%
DGX	16.0B	9.3B	13.66%	10.24%	18.95	1.73	-3.29%	6.68%
NTRA	13.1B	1.2B	17.80%	114.36%	-35.76	10.81	39.26%	33.08%
MEDP	12.2B	2.0B	2.71%	87.82%	38.94	6.2	25.57%	21.62%
CRL	11.4B	4.1B	-3.66%	11.24%	26.02	2.78	0.49%	-11.59%
EXAS	9.3B	2.5B	-20.33%	-38.03%	-38.69	3.67	15.21%	53.51%
MID-CAP
GH	3.1B	603.7M	54.73%	-14.09%	-6.73	5.14	25.21%	30.68%
NEOG	2.9B	929.2M	11.70%	-18.80%	1.9K	3.16	28.93%	111.61%
SMALL-CAP
CDNA	808.3M	275.1M	87.44%	103.94%	-4.41	2.94	-13.93%	-126.97%
ACRS	84.8M	31.1M	-3.25%	-85.34%	-1.1	2.73	0.95%	19.75%
AWH	33.0M	9.2M	-24.07%	-37.65%	-2.24	3.6	11.85%	45.80%
APDN	2.5M	5.5M	-62.31%	120.18%	-0.2	0.45	-68.52%	-141.15%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

bioAffinity Technologies, Inc. News

Latest updates

bioAffinity Technologies, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2
Revenue	8.7%	2,406,391	2,213,356	298,484	19,738	13,542	7,346	1,150	1,306
Cost Of Revenue	-	-	-	74,704	1,234	87.00	-	146	146
Gross Profit	-	-	-	223,780	18,504	834	-	1,004	1,160
Operating Expenses	-6.0%	4,351,621	4,631,786	2,518,284	1,796,854	1,558,804	1,626,379	977,160	685,279
S&GA Expenses	-0.3%	2,185,944	2,192,328	2,023,917	1,426,469	1,169,559	1,133,756	595,702	408,620
R&D Expenses	-9.1%	393,639	432,818	330,376	335,125	369,617	479,925	319,744	248,419
EBITDA Margin	46.8%	-1.60	-3.01	-3.69	-6.94	-10.66	-1,167	-	-
Interest Expenses	-7.0%	23,550	25,325	8,785	1,360	1,655	89,290	896,502	399,265
Income Taxes	60.1%	3,672	2,293	2,294	4,587	11,819	-1.00	300	-
Earnings Before Taxes	17.4%	-1,958,143	-2,370,871	-2,288,590	-1,735,586	-1,520,971	-1,674,583	-4,919,158	-88,052
EBT Margin	45.9%	-1.69	-3.13	-3.80	-7.76	-12.88	-1,697	-	-
Net Income	17.3%	-1,961,815	-2,373,164	-2,290,884	-1,740,173	-1,532,790	-1,674,583	-4,919,458	-88,052
Net Income Margin	45.9%	-1.69	-3.13	-3.81	-7.78	-12.90	-1,697	-	-
Free Cashflow	-48.9%	-2,387,362	-1,602,861	-1,532,682	-1,363,810	-1,561,355	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet								(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2021Q4
Assets	-2.1%	8,049	8,222	10,189	8,873	10,465	12,182	14,063	1,453
Current Assets	-1.0%	3,931	3,973	6,010	8,659	10,233	11,962	14,055	1,438
Cash Equivalents	-13.1%	2,453	2,822	4,500	8,300	9,800	11,414	13,500	1,361
Inventory	-48.7%	9.00	18.00	10.00	10.00	11.00	6.00	6.00	-
Net PPE	0.6%	461	459	512	207	225	214	2.00	5.00
Goodwill	0%	1,404	1,404	1,404	-	-	-	-	-
Liabilities	-17.1%	2,792	3,366	3,196	775	796	1,139	1,464	13,200
Current Liabilities	-21.2%	1,772	2,248	1,959	775	796	1,139	1,464	13,040
Shareholder's Equity	8.3%	5,257	4,855	6,994	8,098	9,668	11,043	12,599	-15,790
Retained Earnings	-4.5%	-46,600	-44,600	-42,200	-39,900	-38,200	-36,667	-34,992	-28,513
Additional Paid-In Capital	4.8%	51,745	49,394	49,161	47,979	47,809	47,652	47,533	12,704
Shares Outstanding	22.6%	11,514	9,395	9,217	8,478	8,463	8,381	4,204	2,677
Float	-	-	-	-	14,000	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)											(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Cashflow From Operations	-45.1%	-2,345	-1,616	-1,532	-1,359	-1,529	-1,300	-1,760	-376	-633	-	-
Share Based Compensation	21.0%	284	235	186	170	158	37.00	79.00	27.00	106	-	-
Cashflow From Investing	-407.9%	-41.39	13.00	-2,186	-3.86	-32.31	-	-	-	-	-	-
Cashflow From Financing	2480.7%	2,019	-84.80	-50.77	-126	-83.32	-563	15,044	-437	301	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BIAF Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net Revenue	$ 2,406,391	$ 921
Operating expenses:
Direct costs and expenses	1,573,441	87
Research and development	393,639	369,617
Clinical development	48,960	19,628
Selling, general and administrative	2,185,944	1,147,875
Depreciation and amortization	149,637	21,684
Total operating expenses	4,351,621	1,558,891
Loss from operations	(1,945,230)	(1,557,970)
Other income (expense):
Interest income	6,127	38,654
Interest expense	(23,550)	(1,655)
Other expense	4,510
Total other expense	(12,913)	36,999
Net loss before provision for income taxes	(1,958,143)	(1,520,971)
Income tax expense	(3,672)	(11,819)
Net loss	$ (1,961,815)	$ (1,532,790)
Net loss per common share, basic	$ (0.20)	$ (0.18)
Net loss per common share, diluted	$ (0.20)	$ (0.18)
Weighted average common shares outstanding, basic	9,915,426	8,433,689
Weighted average common shares outstanding, diluted	9,915,426	8,433,689

BIAF Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 2,453,165	$ 2,821,570
Accounts and other receivables, net	1,123,609	811,674
Inventory	9,487	18,484
Prepaid expenses and other current assets	344,900	321,017
Total current assets	3,931,161	3,972,745
Non-current assets:
Property and equipment, net	461,209	458,633
Operating lease right-of-use asset, net	347,860	370,312
Finance lease right-to-use, net	1,069,601	1,165,844
Goodwill	1,404,486	1,404,486
Intangible assets, net	818,889	833,472
Other assets	16,060	16,060
Total assets	8,049,266	8,221,552
Current liabilities:
Accounts payable	383,993	604,789
Accrued expenses	883,319	1,149,811
Unearned revenue	30,174	33,058
Operating lease liability, current portion	96,631	94,708
Finance lease liability, current portion	372,787	365,463
Notes payable, current portion	4,686
Total current liabilities	1,771,590	2,247,829
Non-current liabilities:
Finance lease liability, net of current portion	739,478	835,467
Operating lease liability, net of current portion	258,110	283,001
Notes payable, net of current portion	23,037
Total liabilities	2,792,215	3,366,297
Commitments and contingencies (See Note 11)
Stockholders’ equity:
Preferred stock, par value $0.001 per share; 20,000,000 shares authorized; no shares issued or outstanding at March 31, 2024, and December 31, 2023
Common stock, par value $0.007 per share; 25,000,000 shares authorized; 11,216,491 and 9,394,610 issued and outstanding at March 31, 2024, and at December 31, 2023, respectively.	78,515	65,762
Additional paid-in capital	51,744,830	49,393,972
Accumulated deficit	(46,566,294)	(44,604,479)
Total stockholders’ equity	5,257,051	4,855,255
Total liabilities and stockholders’ equity	$ 8,049,266	$ 8,221,552

About bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

CEO	Ms. Maria Zannes J.D.
WEBSITE	bioaffinitytech.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	14

bioAffinity Technologies, Inc. Frequently Asked Questions

What is the ticker symbol for bioAffinity Technologies, Inc.? What does BIAF stand for in stocks?

BIAF is the stock ticker symbol of bioAffinity Technologies, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of bioAffinity Technologies, Inc. (BIAF)?

As of Fri May 17 2024, market cap of bioAffinity Technologies, Inc. is 26.11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BIAF stock?

You can check BIAF's fair value in chart for subscribers.

What is the fair value of BIAF stock?

You can check BIAF's fair value in chart for subscribers. The fair value of bioAffinity Technologies, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of bioAffinity Technologies, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BIAF so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is bioAffinity Technologies, Inc. a good stock to buy?

The fair value guage provides a quick view whether BIAF is over valued or under valued. Whether bioAffinity Technologies, Inc. is cheap or expensive depends on the assumptions which impact bioAffinity Technologies, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIAF.

What is bioAffinity Technologies, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, BIAF's PE ratio (Price to Earnings) is -3.12 and Price to Sales (PS) ratio is 5.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIAF PE ratio will change depending on the future growth rate expectations of investors.